Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl‐CoA Carboxylase (ACC) Inhibitor
Year: 2025
Type: article
Study design: Clinical Trial
DOI: 10.1002/jcph.70106
Authors: Manoli Vourvahis, Arthur J. Bergman, Adam G. Ogden, Jim Hughes, James R. Gosset, Amit S. Kalgutkar, Neeta B. Amin
Institution: Pfizer (United States)
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4414510490